PHARMACOLOGICAL CORRECTION OF EXPERIMENTALLY INDUCED OSTEOPOROSIS COMPLICATED BY DIABETES MELLITUS TYPE 2

Abstract

BACKGROUND: Osteoporosis is a significant problem in the world with important medical and economic consequences. An important contribution to solving the problem of osteoporosis can be the creation of drugs based on unique biologically active compounds. aim: Evaluate of the processes of osteogenesis, according to the evaluation of markers of bone remodeling in blood serum at the stages of therapy of experimental osteoporosis complicated by diabetes type 2. Materials and methods: The study was performed on an experimental model of osteoporosis, followed by induction of diabetes type 2, using biochemical methods for analyzing markers of osteoporosis in blood serum. Results: According to the results of the study of the content of markers of bone remodeling, the dependence of the anti-osteoporotic activity of a composite preparation based on succinic acid salts on glucose metabolism disorders in DM is shown. High efficacy of the new drug in monotherapy, and in combination with vitamin D3 in the activation of osteogenesis processes in experimental osteoporosis. it was leveled by a violation of metabolic processes, induction of diabetes type 2. Conclusion: The dependence of the pharmacological effectiveness of the anti-osteoporosis agent on the model of osteoporosis in female rats on metabolic disorders in the form of diabetes type 2 is shown. Keywords: osteoporosis, experimental model, markers of osteogenesis, anti-osteoporosis agent, type 2 diabetes.